The medicine, Blincyto, contains Blinatumomab as an active ingredient with inactive ingredients citric acid monohydrate, lysine hydrochloride, polysorbate 80, trehalose dihydrate...
The medicine, Blincyto, contains Blinatumomab as an active ingredient with inactive ingredients citric acid monohydrate, lysine hydrochloride, polysorbate 80, trehalose dihydrate, and sodium hydroxide. Blinatumomab is a bispecific CD19-directed CD3 T-cell engager that binds to CD19 (expressed on cells of B-lineage origin) and CD3 (expressed on T cells)... Read More
